Screening and the New Treatment for Postpartum Depression.
Journal
Journal of obstetric, gynecologic, and neonatal nursing : JOGNN
ISSN: 1552-6909
Titre abrégé: J Obstet Gynecol Neonatal Nurs
Pays: United States
ID NLM: 8503123
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
medline:
17
11
2023
pubmed:
9
10
2023
entrez:
8
10
2023
Statut:
ppublish
Résumé
In August 2023, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone) as the first oral medication to treat postpartum depression. Despite recommendations to screen and treat depression during pregnancy and after birth, perinatal depression is still considered under-detected and under-treated. In this column, I review screening recommendations and the new pharmacological treatment for postpartum depression, research findings on gaps in the cascade of mental health care, integrative care models, and recommendations from professional organizations on screening and treating postpartum depression within broader systems of mental health care.
Identifiants
pubmed: 37806320
pii: S0884-2175(23)00249-6
doi: 10.1016/j.jogn.2023.09.007
pii:
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
429-441Informations de copyright
Copyright © 2023. Published by Elsevier Inc.